Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:administrativeDivision |
twice daily
|
| gptkbp:chemicalFormula |
C19H20N2O3S
|
| gptkbp:clinicalTrials |
gptkb:Canada
gptkb:United_States Europe Phase 2 Phase 3 |
| gptkbp:collaborations |
academic institutions
research organizations |
| gptkbp:community_service |
cognitive decline
quality of life cognitive assessments CSF amyloid beta levels CSF tau levels functional decline |
| gptkbp:contraindication |
mandatory
|
| gptkbp:developedBy |
Alzheon, Inc.
|
| gptkbp:dosageForm |
based on weight
|
| gptkbp:firstClaim |
cognitive function improvement
|
| gptkbp:formulation |
tablet
|
| gptkbp:funding |
grants
private investment |
| gptkbp:future_plans |
clinical trials
|
| gptkbp:healthcare |
informed consent
age 50 and older diagnosed with Alzheimer's mild to moderate symptoms |
| https://www.w3.org/2000/01/rdf-schema#label |
ALZ-801
|
| gptkbp:market |
high
|
| gptkbp:patentStatus |
patented
|
| gptkbp:regulatoryCompliance |
under investigation
|
| gptkbp:releaseYear |
2015
|
| gptkbp:researchFocus |
neurodegenerative diseases
neuroprotective agents long-term outcomes Alzheimer's treatment disease-modifying therapies symptomatic treatments |
| gptkbp:researchInterest |
yes
peer-reviewed journals clinical trial results efficacy studies mechanism of action studies safety studies |
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
headache
nausea diarrhea |
| gptkbp:status |
investigational
|
| gptkbp:targets |
Alzheimer's disease
amyloid hypothesis patients with mild to moderate Alzheimer's disease |
| gptkbp:triggerType |
inhibition of amyloid beta aggregation
|